Source - SMW
Creo Medical Group  - a medical device company focused on the emerging field of surgical endoscopy - has announced the first clinical use of the company's Speedboat device.   It said the first patient with a large pre-cancerous lesion in the gastrointestinal (GI) tract was treated using Creo's Speedboat device powered by Creo's CROMA electrosurgery advanced energy platform.  

The patient was treated by Professor Brian Saunders at St. Mark's Hospital in London, United Kingdom.

At 9:59am: (LON:CREO) Creo Medical Group Plc Ord Gbp0.001 share price was +3p at 81.5p